TY - JOUR
T1 - Evaluation criteria for musculoskeletal and craniofacial tissue engineering constructs
T2 - A conference report
AU - Butler, David L.
AU - Lewis, Jack L.
AU - Frank, Cyril B.
AU - Banes, Albert J.
AU - Caplan, Arnold I.
AU - De Deyne, Patrick G.
AU - Dowling, Mary Ann
AU - Fleming, Braden C.
AU - Glowacki, Julie
AU - Guldberg, Robert E.
AU - Johnstone, Brian
AU - Kaplan, David L.
AU - Levenston, Marc E.
AU - Lotz, Jeffrey C.
AU - Ed, Yiling Lu
AU - Lumelsky, Nadya
AU - Mao, Jeremy J.
AU - Mauck, Robert L.
AU - McDevitt, Cahir A.
AU - Mejia, Lito C.
AU - Murray, Martha
AU - Ratcliffe, Anthony
AU - Spindler, Kurt P.
AU - Tashman, Scott
AU - Wagner, Christopher T.
AU - Weisberg, Elijah M.
AU - Williams, Chrysanthi
AU - Zhang, Renwen
PY - 2008/11/1
Y1 - 2008/11/1
N2 - Over the past 20 years, tissue engineering (TE) has evolved into a thriving research and commercial development field. However, applying TE strategies to musculoskeletal (MSK) and craniofacial tissues has been particularly challenging since these tissues must also transmit loads during activities of daily living. To address this need, organizers invited a small group of bioengineers, surgeons, biologists, and material scientists from academia, industry, and government to participate in a 21/2-day conference to develop general and tissue-specific criteria for evaluating new concepts and tissue-engineered constructs, including threshold values of success. Participants were assigned to four breakout groups representing commonly injured tissues, including tendon and ligament, articular cartilage, meniscus and temporomandibular joint, and bone and intervertebral disc. Working in multidisciplinary teams, participants first carefully defined one or two important unmet clinical needs for each tissue type, including current standards of care and the potential impact of TE solutions. The groups then sought to identify important parameters for evaluating repair outcomes in preclinical studies and to specify minimally acceptable values for these parameters. The importance of in vitro TE studies was then discussed in the context of these preclinical studies. Where data were not currently available from clinical, preclinical, or culture studies, the groups sought to identify important areas of preclinical research needed to speed the development process. This report summarizes the findings of the conference.
AB - Over the past 20 years, tissue engineering (TE) has evolved into a thriving research and commercial development field. However, applying TE strategies to musculoskeletal (MSK) and craniofacial tissues has been particularly challenging since these tissues must also transmit loads during activities of daily living. To address this need, organizers invited a small group of bioengineers, surgeons, biologists, and material scientists from academia, industry, and government to participate in a 21/2-day conference to develop general and tissue-specific criteria for evaluating new concepts and tissue-engineered constructs, including threshold values of success. Participants were assigned to four breakout groups representing commonly injured tissues, including tendon and ligament, articular cartilage, meniscus and temporomandibular joint, and bone and intervertebral disc. Working in multidisciplinary teams, participants first carefully defined one or two important unmet clinical needs for each tissue type, including current standards of care and the potential impact of TE solutions. The groups then sought to identify important parameters for evaluating repair outcomes in preclinical studies and to specify minimally acceptable values for these parameters. The importance of in vitro TE studies was then discussed in the context of these preclinical studies. Where data were not currently available from clinical, preclinical, or culture studies, the groups sought to identify important areas of preclinical research needed to speed the development process. This report summarizes the findings of the conference.
UR - http://www.scopus.com/inward/record.url?scp=56549120412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56549120412&partnerID=8YFLogxK
U2 - 10.1089/ten.tea.2007.0383
DO - 10.1089/ten.tea.2007.0383
M3 - Article
C2 - 19093294
AN - SCOPUS:56549120412
SN - 1937-3341
VL - 14
SP - 2089
EP - 2104
JO - Tissue Engineering - Part A
JF - Tissue Engineering - Part A
IS - 12
ER -